Connect Biopharma Reports Positive Rademikibart Data

Connect Biopharma has announced positive topline results from its Phase 1 study of intravenous rademikibart in patients with asthma or COPD. The study administered a single 300 mg dose via a 2-minute IV push, showing rapid therapeutic effects. These findings indicate that intravenous rademikibart could be a viable and effective treatment option for respiratory conditions, potentially offering a new avenue for patient care and disease management in these patient populations.